Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.39 |
| ▸ | CLK1 | P49759 | 2/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 8/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9983127 | 0.90 | BTK (0.47) | DYRK1AMAOACHEK2CLK1CDK5 | |
| SCHEMBL9983911 | 0.83 | JAK2 (0.41) | DYRK1AMAOABTKJAK2GABRA1 | |
| SCHEMBL12070654 | 0.82 | BTK (0.49) | BTK | |
| SCHEMBL12071971 | 0.82 | BTK (0.43) | DYRK1ACLK1CDK5CDK5R1CHEK1 | |
| SCHEMBL12070477 | 0.82 | BTK (0.44) | DYRK1AMAOABTKJAK2 | |
| SCHEMBL12070651 | 0.81 | BTK (0.43) | DYRK1AMAOABTKJAK2GRM4 | |
| SCHEMBL9983601 | 0.80 | BTK (0.36) | DYRK1AMAOACLK1CDK5CDK5R1 | |
| SCHEMBL9984220 | 0.80 | BTK (0.47) | DYRK1AMAOACHEK2CLK1CDK5 | |
| SCHEMBL9983906 | 0.79 | DYRK1A (0.43) | DYRK1AMAOACHEK2CLK1CDK5 | |
| SCHEMBL9983568 | 0.79 | BTK (0.57) | BTKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582668-B1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2582668-B1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2582668-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20130096118-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-04-18 | — | — | US | disclosed |
| US-20130096118-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-04-18 | — | — | US | disclosed |
| WO-2011159857-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159857-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096118-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, PRKACA, CILK1 | DYRK1A 109/4885MAOA 2275/4885CHEK2 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.